Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01651806 · ClinicalTrials.gov registry record · Phase 2
Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty
A Phase 2 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01651806 is a Phase 2 study that has completed, run by Rush University Medical Center. The registered enrollment target is 65 participants.
The verdict
NCT01651806, a Phase 2 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
Hypotheses: Primary - A weighted dose of 20 mg/kg of tranexamic acid will be more efficacious than a single uniform dose of 1 gram in primary total knee arthroplasty (TKA) cases. This includes having a greater impact on decreasing blood loss without increasing the occurrence of adverse thromboembolic events in patients undergoing primary, elective total knee arthroplasty. Secondary - TA will decrease blood loss more effectively in women than in men undergoing this procedure.
Interventions
- DRUG Tranexamic Acid standard dose
- DRUG Females Tranexamic Acid weighted dose
- DRUG Females receiving a uniform dose of TA
- DRUG Males Weighted Dose TA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01651806
The ClinicalTrials.gov registry entry for NCT01651806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tranexamic Acid standard dose is the first listed.
NCT01651806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01651806 about?
NCT01651806 is a clinical study titled "Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty". Hypotheses: Primary - A weighted dose of 20 mg/kg of tranexamic acid will be more efficacious than a single uniform dose of 1 gram in primary total knee arthroplasty (TKA) cases. This includes having a greater impact on decreasing blood loss without increasing the occurrence of adverse thromboemboli...
What is the current status of trial NCT01651806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2012-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01651806?
The interventions under investigation include: Tranexamic Acid standard dose (DRUG), Females Tranexamic Acid weighted dose (DRUG), Females receiving a uniform dose of TA (DRUG), Males Weighted Dose TA (DRUG).
Who is sponsoring clinical trial NCT01651806?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.